The company’s Gene Traffic Control platform is used to study and modulate the chromatin regulatory system. The company is pursuing multiple treatments for breakdowns in this system.
Adrian is president and chief executive officer of Foghorn Therapeutics. An experienced leader in biotech, Adrian is interested in solving complex issues at the intersection of science, medicine, and business on a global scale to help people and families dealing with diseases.
David Schenkein, MD, is general partner and co-leader of Google Ventures’ life science team. He has been a hematologist and medical oncologist for more than 20 years and was the chief executive officer of Agios.
José Baselga, MD, PhD, conducted laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab, and everolimus, and contributed to more than 470 peer-reviewed publications.
Marina Nelen, PhD, joined Foghorn Therapeutics in 2018. She brings more than 20 years of experience in small molecule drug discovery from assay development and screening to Lead Optimization (LO).
Foghorn Therapeutics, Inc. and its affiliates collect, use, disclose, and process personal information online. The privacy policy does not cover clinical trials or data collected from employees or contractors.
